160 related articles for article (PubMed ID: 20104215)
1. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.
Armstrong RG; West J; Card TR
Am J Gastroenterol; 2010 Jul; 105(7):1604-9. PubMed ID: 20104215
[TBL] [Abstract][Full Text] [Related]
2. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
3. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
4. Use of azathioprine and the risk of cancer in inflammatory bowel disease.
Pasternak B; Svanström H; Schmiegelow K; Jess T; Hviid A
Am J Epidemiol; 2013 Jun; 177(11):1296-305. PubMed ID: 23514635
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.
Kandiel A; Fraser AG; Korelitz BI; Brensinger C; Lewis JD
Gut; 2005 Aug; 54(8):1121-5. PubMed ID: 16009685
[TBL] [Abstract][Full Text] [Related]
6. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
[TBL] [Abstract][Full Text] [Related]
7. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
[TBL] [Abstract][Full Text] [Related]
8. A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease.
Wilson JC; Furlano RI; Jick SS; Meier CR
J Gastroenterol; 2016 Nov; 51(11):1050-1062. PubMed ID: 27056729
[TBL] [Abstract][Full Text] [Related]
9. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
Lakatos PL; Lovasz BD; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Golovics PA; Vegh Z; Mandel M; Horvath A; Szathmari M; Kiss LS; Lakatos L
J Crohns Colitis; 2013 Jun; 7(5):385-91. PubMed ID: 22766526
[TBL] [Abstract][Full Text] [Related]
10. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.
Fraser AG; Orchard TR; Robinson EM; Jewell DP
Aliment Pharmacol Ther; 2002 Jul; 16(7):1225-32. PubMed ID: 12144571
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.
Koller T; Galambosova M; Filakovska S; Kubincova M; Hlavaty T; Toth J; Krajcovicova A; Payer J
World J Gastroenterol; 2017 Jun; 23(22):4102-4111. PubMed ID: 28652663
[TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of azathioprine therapy.
McGovern DP; Jewell DP
Gut; 2005 Aug; 54(8):1055-9. PubMed ID: 16009676
[TBL] [Abstract][Full Text] [Related]
13. Azathioprine and mercaptopurine: lymphoma.
Prescrire Int; 2011 May; 20(116):126. PubMed ID: 21648178
[TBL] [Abstract][Full Text] [Related]
14. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of colorectal cancer in inflammatory bowel disease.
Bansal P; Sonnenberg A
Am J Gastroenterol; 1996 Jan; 91(1):44-8. PubMed ID: 8561142
[TBL] [Abstract][Full Text] [Related]
16. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
17. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
Jones JL; Loftus EV
Inflamm Bowel Dis; 2007 Oct; 13(10):1299-307. PubMed ID: 17600819
[TBL] [Abstract][Full Text] [Related]
18. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.
Bermejo F; Lopez-Sanroman A; Taxonera C; Gisbert JP; Pérez-Calle JL; Vera I; Menchén L; Martín-Arranz MD; Opio V; Carneros JA; Van-Domselaar M; Mendoza JL; Luna M; López P; Calvo M; Algaba A
Aliment Pharmacol Ther; 2008 Sep; 28(5):623-8. PubMed ID: 18513380
[TBL] [Abstract][Full Text] [Related]
19. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study.
Kopylov U; Vutcovici M; Kezouh A; Seidman E; Bitton A; Afif W
Inflamm Bowel Dis; 2015 Aug; 21(8):1847-53. PubMed ID: 25993693
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
